| Full text | |
| Author(s): Show less - |
Tabata M. Silva
[1]
;
Fernanda C. F. Moretto
[2]
;
Maria T. De Sibio
[3]
;
Bianca M. Gonçalves
[4]
;
Miriane Oliveira
[5]
;
Regiane M. C. Olimpio
[6]
;
Diego A. M. Oliveira
[7]
;
Sarah M. B. Costa
[8]
;
Igor C. Deprá
[9]
;
Vickeline Namba
[10]
;
Maria T. Nunes
[11]
;
Célia R. Nogueira
[12]
Total Authors: 12
|
| Affiliation: Show less - | [1] Universidade Estadual Paulista. Faculdade de Medicina de Botucatu. Departamento de Medicina Interna - Brasil
[2] Universidade Estadual Paulista. Faculdade de Medicina de Botucatu. Departamento de Medicina Interna - Brasil
[3] Universidade Estadual Paulista. Faculdade de Medicina de Botucatu. Departamento de Medicina Interna - Brasil
[4] Universidade Estadual Paulista. Faculdade de Medicina de Botucatu. Departamento de Medicina Interna - Brasil
[5] Universidade Estadual Paulista. Faculdade de Medicina de Botucatu. Departamento de Medicina Interna - Brasil
[6] Universidade Estadual Paulista. Faculdade de Medicina de Botucatu. Departamento de Medicina Interna - Brasil
[7] Universidade Estadual Paulista - Brasil
[8] Universidade Estadual Paulista. Faculdade de Medicina de Botucatu. Departamento de Medicina Interna - Brasil
[9] Universidade Estadual Paulista. Faculdade de Medicina de Botucatu. Departamento de Medicina Interna - Brasil
[10] Universidade Estadual Paulista. Faculdade de Medicina de Botucatu. Departamento de Medicina Interna - Brasil
[11] Universidade de São Paulo. Instituto de Ciências Biomédicas. Departamento de Fisiologia e Biofísica - Brasil
[12] Universidade Estadual Paulista. Faculdade de Medicina de Botucatu. Departamento de Medicina Interna - Brasil
Total Affiliations: 12
|
| Document type: | Journal article |
| Source: | ARCHIVES OF ENDOCRINOLOGY METABOLISM; v. 63, n. 2, p. 142-147, 2019-03-21. |
| Abstract | |
ABSTRACT Objective: To verify the physiological action of triiodothyronine T3 on the expression of transforming growth factor α (TGFA) mRNA in MCF7 cells by inhibition of RNA Polymerase II and the MAPK/ERK pathway Materials and methods: The cell line was treated with T3 at a physiological dose (10−9M) for 10 minutes, 1 and 4 hour (h) in the presence or absence of the inhibitors, α-amanitin (RNA polymerase II inhibitor) and PD98059 (MAPK/ERK pathway inhibitor). TGFA mRNA expression was analyzed by RT-PCR. For data analysis, we used ANOVA, complemented with the Tukey test and Student t-test, with a minimum significance of 5%. Results: T3 increases the expression of TGFA mRNA in MCF7 cells in 4 h of treatment. Inhibition of RNA polymerase II modulates the effect of T3 treatment on the expression of TGFA in MCF7 cells. Activation of the MAPK/ERK pathway is not required for T3 to affect the expression of TGFA mRNA. Conclusion: Treatment with a physiological concentration of T3 after RNA polymerase II inhibition altered the expression of TGFA. Inhibition of the MAPK/ERK pathway after T3 treatment does not interfere with the TGFA gene expression in a breast adenocarcinoma cell line. (AU) | |
| FAPESP's process: | 14/15209-5 - PARTICIPATION OF T3 IN POST-TRANSCRIPTIONAL CONTROL OF HIF-1± AND TGF± EXPRESSION IN CELL LINES OF BREAST CANCER AND EVALUATION OF THE INVOLVEMENT OF POTENTIAL miRNAS |
| Grantee: | Fernanda Cristina Fontes Moretto |
| Support Opportunities: | Scholarships in Brazil - Doctorate |
| FAPESP's process: | 13/05629-4 - Genomic vs nongenomic actions of thyroid hormones: changes of paradigms, physiological implications and therapeutical perspectives |
| Grantee: | Maria Tereza Nunes |
| Support Opportunities: | Research Projects - Thematic Grants |
| FAPESP's process: | 15/09686-8 - Mechanism of action of triiodothyronine hornone (T3) in the TGFa gene expression in breast adenocarcinoma cell lines |
| Grantee: | Tabata Marinda da Silva |
| Support Opportunities: | Scholarships in Brazil - Scientific Initiation |